David R. Margrave - Sep 19, 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
Chief Financial Officer
Signature
/s/ David R. Margrave
Stock symbol
LTRN
Transactions as of
Sep 19, 2025
Transactions value $
$0
Form type
4
Date filed
9/23/2025, 04:05 PM
Previous filing
Jul 17, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Margrave David R. Chief Financial Officer 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS /s/ David R. Margrave 2025-09-22 0001813162

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -78.3K -100% $0.00 0 Jun 15, 2020 Common Stock 78.3K $15.00 Direct F1
transaction LTRN Stock Option (Right to Buy) Award $0 +78.3K $0.00 78.3K Jun 15, 2020 Common Stock 78.3K $5.04 Direct F1
transaction LTRN Stock Option (Right to Buy) Disposed to Issuer $0 -26.1K -100% $0.00 0 Oct 29, 2021 Common Stock 26.1K $10.21 Direct F2
transaction LTRN Stock Option (Right to Buy) Award $0 +26.1K $0.00 26.1K Oct 29, 2021 Common Stock 26.1K $5.04 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).
F2 The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 29, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing November 29, 2021.